✦ LIBER ✦

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

✍ Scribed by Ghamande, Sharad; Lin, Chia-Chi; Cho, Daniel C.; Shapiro, Geoffrey I.; Kwak, Eunice L.; Silverman, Michael H.; Tseng, Yunlong; Kuo, Min-Wen; Mach, Wendy B.; Hsu, Shu-Chi; Coleman, Teresa; Yang, James Chih-Hsin; Cheng, Ann-Lii; Ghalib, Mohammad H.; Chuadhary, Imran; Goel, Sanjay

Book ID: 121599070
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 318 KB
Volume: 32
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-0044-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Open-label, dose-escalation, safety, pha

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors

✍ M. W. Saif, C. Erlichman, T. Dragovich… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 447 KB

365 A Phase 1b Open-label, Dose-escalati

365 A Phase 1b Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0941 in Combination with Erlotinib in Patients with Advanced Solid Tumors

✍ Lolkema, M.; Leong, S.; Voest, E.; Freas, E.; Shankar, G.; Brachmann, R.K.; Moss 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 78 KB

218 POSTER A phase I dose-escalation stu

218 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors

✍ E. Calvo; G. Edelman; J. Baselga; E. Kwak; C. Scheffold; L. Nguyen; G.I. Shapiro 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB

A Phase I study to assess the safety, to

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

✍ J. R. Infante; R. Kurzrock; J. Spratlin; H. A. Burris; S. G. Eckhardt; J. Li; K. 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 338 KB

377 A phase 1, dose-escalation, safety,

377 A phase 1, dose-escalation, safety, pharmacokinetic and pharmacodynamic study of PF-03732010, an IgG1 monoclonal antibody against P-cadherin (placental), administered to adult patients with advanced solid tumors

✍ Y. Bang; R. Cohen; T. Blumenkopf; Y. Zhang; M. Toh; A. Countouriotis; D. Shalins 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

372 A phase I dose-escalation study of t

372 A phase I dose-escalation study of the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously to patients with advanced solid tumors

✍ C. Weekes; P. Hedge; Y. Xin; R. Yu; H. Xiang; L. Gore; M. Beeram; R. Brachmann; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB